(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Moon milestones: A rundown of Artemis 2's many spaceflight firsts - 2Sweet Taste? Candy Fulfills You
- 3Heart disease risk greater for women with a common condition they may not be aware they have
- 4Reviving Your Home with Nutritious Indoor Plants
- 5If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- Hezbollah uses ambulances, paramedic uniforms, as disguise for terrorist activity, IDF says
- Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- Paraplegic engineer becomes the first wheelchair user to blast into space
- UN experts urge investigation into Israel’s killing of Lebanese journalists
- Extreme Manual for Picking a Camper Van
- Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- The Excursion to Monetary Proficiency: Individual budget Triumphs
- Experience Sports in Dubai: A Daredevil's Aide
- Unwinding the Starting points of America: An Excursion Through History
